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Background: We reviewed the effectiveness and safety of cardiac resynchronization therapy (CRT) for
patients with New York Heart Association (NYHA) class IV non-ambulatory heart failure (NAHF).
Methods: From 2006 to 2011, 310 patients underwent CRT at Kobe University Hospital and Himeji
Cardiovascular Center because of heart failure. Of these, 29 NAHF patients were retrospectively analyzed.
The control group comprised 21 age- and ejection fraction-matched patients with NAHF who did not
undergo CRT from the ICU database of Kobe University Hospital. The primary endpoint was all-cause
death and hospitalization for heart failure. Response was deﬁned as a 415% reduction in left ventricular
end-systolic volume (LVESV).
Results: CRT was performed successfully without serious complications in all patients. Twenty-three
patients (79%) were discharged 19715 days after CRT implantation, while 6 (21%) died during their
hospital stay due to progressive heart failure. Compared with the control group, patients in the CRT
group showed signiﬁcant improvements in the primary endpoint (log-rank p¼0.04). Six patients (21%)
were deﬁned as responders and the Kaplan–Meier curve showed that responders experienced a better
outcome than non-responders (log-rank p¼0.029). LV dyssynchrony before implantation was signiﬁ-
cantly related to the occurrence of the primary endpoint (p¼0.02).
Conclusions: CRT can be safely used in patients with NAHF and can improve long-term patient outcomes,
especially in treatment responders.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V.
1. Introduction
Cardiac resynchronization therapy (CRT) is an effective treat-
ment for patients with New York Heart Association (NYHA) class
III–IV heart failure with impaired systolic failure. CRT improves
exercise capacity and quality of life in addition to reducing heart
failure hospitalizations and overall mortality. However, large CRT
trials have not included patients with severe heart failure such as
those dependent on intravenous inotropic drugs [1–3]. Further-
more, the 2012 ACCF/AHA/HRS Focused Update of the 2008
Guidelines for Device-Based Therapy includes no mention of CRT
for patients with non-ambulatory NYHA class IV (NAHF) [4]. As
previously reported, the long-term survival of patients with NAHF
varies according to patient population and the application of
devices and medical therapy [5–7]. In the REMATCH trial [7], the
six-month mortality rate in the optimal medical therapy cohort
was 61%. While occasionally described as beneﬁcial in patients
with NAHF, CRT is not generally used as a “rescue therapy” for such
patients. Furthermore, cardiac transplantation and left ventricular
assist devices (LVADs) are not common therapies, especially in
elderly patients. Therefore, we retrospectively assessed the effec-
tiveness and safety of CRT for patients with NAHF.
2. Material and methods
2.1. Study design
This was a retrospective database study of patients who under-
went CRT from two centers, Kobe University Hospital (Kobe, Japan)
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and Himeji Cardiovascular Center (Himeji, Japan). The database
included 310 patients who received CRT between 2003 and 2011.
Of these, we identiﬁed 44 patients with end-stage heart failure
who required intravenous diuretics and/or inotropes and/or intra-
aortic balloon pump (IABP) support for life maintenance at the
point of CRT implantation. Weaning of intravenous drugs was
attempted in all patients, but discharge from the intensive care
unit (ICU) was not achieved. We excluded patients who required
hospitalization due to reversible factors leading to heart failure
decompensation such as an afterload mismatch, infection, acute
myocardial infarction, or medically refractory arrhythmias.
In accordance with the above criteria, 29 patients were enrolled
in this study. All patients gave their written informed consent and
agreed to undergo CRT implantation with an awareness of the
increased risk due to their critical condition. The study conformed
to the principles of the Declaration of Helsinki.
Patients with NAHF with no indication for CRT served as a
comparison group. The ICU database of Kobe University Hospital
followed a total of 322 patients who were admitted to the ICU for
heart failure decompensation between 2007 and 2012. Of these, 21
age- and ejection fraction (EF)-matched patients who required
intravenous drugs for more than 2 weeks were enrolled in the
control group. Same as in the CRT group, patients with heart
failure due to reversible factors were excluded. Patient character-
istics and clinical outcomes were reviewed.
Patient data were analyzed to determine the primary endpoint of
all-cause mortality and post-implantation hospitalization for heart
failure. After 6 months of follow-up, patients were classiﬁed as
responders to CRT if they showed a more than 15% relative decrease
in LVESV (left ventricular end-systolic volume) from baseline. Non-
response was deﬁned as an LVESV improvement of less than 15% or
death within 6 months of implantation. Blood pressure and heart rate
were recorded just before CRT implantation. Brain natriuretic peptide
(BNP), creatinine, and sodium levels were measured at the time of
admission (pre-implantation). Hemoglobin and albumin levels mea-
sured during patients' hospitalization before implantation were
selected as the minimum levels. The QRS width and conﬁguration
were measured using a 12-lead ECG at the time of admission.
2.2. Implantation techniques
All patients were implanted with Medtronic (Minnesota, USA),
St. Jude Medical (California, USA), or Boston Scientiﬁc (Massachu-
setts, USA) CRT devices. The LV lead was implanted in a branch of
the coronary sinus, with the exception of one case in which it was
implanted in the epicardial ventricular wall. This patient's cor-
onary sinus could not be approached endovascularly because of an
anomalous coronary vein. Right atrial (RA) and right ventricular
(RV) leads were implanted in the RA appendage and RV apex,
respectively. Lead positioning was assessed from post-operative
chest X-rays in the anterior and lateral views.
If patients were in sinus rhythm, the atrio-ventricular delay
was optimized individually based on an echocardiographic assess-
ment of transmitral ﬂow. The V-V delay was programmed to
achieve the greatest degree of biventricular fusion by measure-
ment of the echocardiographic time velocity index.
In patients with atrial ﬁbrillation (AF), if biventricular pacing
could not predominate over their intrinsic rhythm, a radiofre-
quency atrio-ventricular junctional ablation was performed after
CRT implantation. The decision to implant a CRT-D or CRT-P device
was left to the discretion of each physician.
2.3. Follow-up
Follow-up data were collected retrospectively after CRT
implantation. All study patients were followed-up regularly in
our hospitals. Patients visited the CRT clinic at one month, three
months, and every three months thereafter. In addition to a medical
interview, an electrocardiogram, chest X-ray, NYHA functional class
assessment, biomarker level measurements (including BNP and crea-
tinine), and CRT interrogations were performed at each follow-up visit.
A standard echocardiography was performed at six months of follow-
up in all patients. If patients died outside our hospitals, we contacted
their families by phone and checked the cause of death.
2.4. Echocardiographic study and analysis
All echocardiographic studies were recorded by commercially
available echocardiography systems. LV volumes and EF were
assessed using the biplane Simpson's method. The severity of
mitral regurgitation (MR) was assessed from color-ﬂow Doppler
images in the apical four-chamber view. MR was classiﬁed as
grade 1 (jet area/left atrium area o20%), grade 2 (jet area/left
atrium area of 20–40%), or grade 3 (jet area/left atrium area
440%). Digital data were retrospectively analyzed by dedicated
software (Ultra Extend, Toshiba Medical System, Tochigi, Japan) for
an off-line analysis. Baseline LV dyssynchrony was evaluated by
speckle-tracking radial strain from the mid-LV short-axis images.
LV dyssynchrony was deﬁned according to the time interval
between the anteroseptal and posterior wall segmental peak
strains [8,9]. Four patients who depended on ventricular pacing
due to AV block were analyzed during RV pacing.
2.5. Statistical analysis
Continuous data are presented as the mean7SD. Differences
between means were compared using the Student's t-test for
Gaussian variables. For non-Gaussian variables, data were com-
pared using the Mann–Whitney test for independent samples or
the Wilcoxon nonparametric test for paired samples. Categorical data
are presented as percentages, with differences compared using a chi-
square analysis. Cumulative event proportions were calculated with a
Kaplan–Meier analysis, and differences in patient outcomes were
assessed by the log-rank test. P-values of less than 0.05 were
considered statistically signiﬁcant. Statistical analyses were performed
using SPSS version 20.0 software (Chicago, IL, USA).
3. Results
3.1. Baseline characteristics
The study population included 18 men (62%). The mean patient
age was 67712 years. The cause of heart failure was ischemic in 9
(31%) patients and non-ischemic in 20 (69%) patients. Twenty-ﬁve
(86%) patients were implanted with a CRT-D device. The mean QRS
width was 164738 ms, and a left bundle branch block (LBBB) was
noted in 14 patients (48%). Six (20%) patients were upgraded to
CRT from a pacemaker or implantable cardioverter-deﬁbrillator
(ICD). Only one patient had a QRSo120 ms, but a decision to
implant a CRT device was made because echocardiography
revealed LV dyssynchrony. Five (17%) patients presented with
chronic AF and 10 (35%) presented with paroxysmal AF. Of these,
seven (24%) patients were referred for AV node ablation to achieve
control of the ventricular rate. Six (13%) patients required IABP to
control their heart failure before implantation. At the time of
implantation, all patients required some type of intravenous
medication: 19 (65%) patients required inotropes, 18 (62%)
required diuretics, and 13 (45%) required vasodilators. On the
echocardiographic data, severe LV dilatation was observed in most
patients [mean LVEDV of 195777 mL and mean LVESV of
1517164 mL], with a mean LVEF of 2376%. LVEF was below
S. Yamashita et al. / Journal of Arrhythmia 31 (2015) 221–225222
35% in all patients. The MR grade was 1.571.1. Radial strain
demonstrated substantial LV dyssynchrony in this population
(240794 ms). At the time of implantation, 48% were using beta-
blockers and 58% were using angiotensin-converting enzyme
inhibitors or angiotensin II receptor blockers. The baseline char-
acteristics are summarized in Table 1. Table 2 shows a comparison
of characteristics between the CRT and control groups. Age, blood
pressure, and LVEF were comparable between the two groups.
However, QRS width was signiﬁcantly greater in the CRT group
than in controls (164738 ms vs. 103723 ms; po0.05).
3.2. Outcomes
CRT implantation was performed successfully without any
serious complications in all patients, with the exception of one
patient who could not be implanted due to a venous anomaly, as
mentioned above. After implantation, all patients showed
improvements of both systolic and diastolic blood pressures (with
a mean systolic blood pressure increase of 876 mmHg). It was
possible to wean all patients from intravenous medications after
implantation, although six (21%) patients died of heart failure in
the hospital without being discharged.
A post-implantation Kaplan–Meier curve is shown in Fig. 1.
During follow-up, no patient received a cardiac transplantation or
LVAD. Compared with controls, patients in the CRT group showed
signiﬁcant improvements in the primary endpoint (log-rank
p¼0.04). In the CRT group, 23 (79%) patients reached the primary
endpoint and 17 (59%) patients died of cardiac causes. Two of
these (7%) were identiﬁed as sudden deaths. One sudden death
patient was implanted with a CRT-D device, and device interroga-
tion revealed no life-threatening arrhythmias. The other patient
was implanted with a CRT-P device, and the cause of his sudden
death is unknown because we were unable to interrogate the
device. Other causes of death were pneumonia, malignancy,
systemic thrombosis, and pyogenic spondylitis.
Device-related infections were observed in two (7%) patients.
One case occurred 344 days after implantation. We removed the
infected device and re-implanted a new one. Another case
occurred 224 days after implantation. The infected device was
removed but the patient was not re-implanted because he did not
respond to bi-ventricular pacing. A dislodgement of the LV lead
was observed in one (3%) patient who was re-implanted.
In the control group, 10 patients (48%) died of heart failure
without discharge. Although the other 11 patients (52%) were
discharged, ﬁve (24%) died of heart failure and two (10%) died of
non-cardiac causes. There were signiﬁcant fewer in-hospital
deaths in the CRT group than in controls (20% vs. 48%, po0.05).
3.3. Responder vs. non-responder
In accordance with the above criteria, six patients were
classiﬁed as responders. The Kaplan–Meier curve showed a better
Table 1
Baseline characteristics.
Total 29
Age, y 67712
Male, n 18(62%)
CRTD, n 25(86%)
Upgrade, n 6(20%)
Ischemic cardiomyopathy, n 9(31%)
Systolic blood pressure, mmHg 97716
Resting heart rate, bpm 82715
Intravenous inotropic agents, n 19(65%)
Intravenous vasodilator agents, n 13(45%)
Prior IABP, n 6(20%)
Chronic atrial ﬁbrillation, n 5(17%)
Paroxysmal atrial ﬁbrillation, n 10(35%)
AV node ablation, n 7(24%)
LVEF, % 2376
LVEDV, mL 195777
LVESV, mL 151764
LV radial dyssynchrony, ms 240794
MR, degree 1.871.1
LBBB 13(45%)
QRS width, ms 164733
Medication, n
β-blocker 14(48%)
ACE-I/ARB 17(58%)
Diuretics 25(86%)
Spironolactone 19(65%)
Digitalis 5(17%)
Hemoglobin, g/dL 11.072.0
Creatinine 41.5 mg/dL, n 12(42%)
Hemodialysis 2(6%)
Sodium, mmol/L 13574
Albumin, g/dL 3.270.4
BNP, pg/mL 12997808
CRTD, cardiac resynchronization therapy combined with an
implantable deﬁbrillator; IABP, intra-aortic balloon pumping; AV
node ablation, atrio-ventricular node ablation; LVEF, left ventricular
ejection fraction; LVEDV, left ventricular end-diastolic volume;
LVESV, left ventricular end-systolic volume; MR, mitral regurgia-
tion; LBBB, left bundle branch block; ACE-I, angiotensin-converting
enzyme inhibitor; ARB, angiotensin II receptor blocker; BNP, brain
natriuretic peptide.
Table 2
Baseline parameters of CRT patients and controls.
CRT (n¼29) Control (n¼21) p-Value
Age, y 67712 6978 0.39
Systolic BP, mmHg 97716 96715 0.14
Ischemic cardiomyopathy, n 9 (31%) 9 (43%) 0.39
QRS width, ms 164738 103723 o0.01
LVEF, % 2376 2575 0.12
BP, blood pressure; LVEF, left ventricular ejection fraction.
Fig. 1. Kaplan–Meier survival curves for all patients without death fromworsening
heart failure (HF) or hospitalization for deteriorating HF after cardiac resynchroni-
zation therapy (CRT). Compared with controls, patients in the CRT group showed
signiﬁcant improvements in the primary endpoint.
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outcome in responders than in non-responders (log-rank p¼
0.029; Fig. 2). A comparison of baseline clinical and echocardio-
graphic characteristics between responders and non-responders is
shown in Table 3. Responders had signiﬁcantly greater LV dyssyn-
chrony (341 ms vs. 218 ms, p¼0.02) and higher albumin levels
(3.6 vs. 3.2, p¼0.03). The presence of LBBB and QRS width were
not associated with response. In the responder group, two patients
were implanted in the lateral vein and four were implanted in the
posterolateral vein. No one was implanted in the anterolateral or
posterior veins. As a result, there was no statistical relationship
between the response to CRT and the LV lead position.
Fig. 3 shows the plot of LV dyssynchrony in patients with and
without cardiovascular events. A total of 26 (89%) patients pre-
sented with LV dyssynchrony above 130 ms. All three patients with
LV dyssynchrony below 130 ms reached the primary endpoint.
Patients without cardiovascular events presented with signiﬁ-
cantly greater LV dyssynchrony than that in patients with events
(p¼0.02).
4. Discussion
The major ﬁndings of our study are as follows. First, a CRT
device can be safely implanted in NAHF patients without any
serious complications. Second, CRT reduces the number of in-
hospital deaths without discharge. Third, CRT reduces mortality
and hospitalization for heart failure in this severely afﬂicted
population, especially if they are responders.
Previously, various small studies reported that CRT is an
effective therapy in patients with NAHF [7,10–15]. These studies
demonstrated favorable outcomes in patients treated with CRT,
including the ability to wean patients from intravenous inotropes
to oral drugs. Milliez et al. demonstrated an acute hemodynamic
and biological improvement in 20 dobutamine-dependent
patients with NAHF following CRT implantation [14]. A marked
blood pressure elevation with a mean systolic blood pressure
increase of 15 mmHg was observed in all patients. This led to a
rapid improvement of urine output, biological markers of renal
function, and BNP levels. Theodorakis et al. reported on long-term
prognosis in 18 patients with NAHF who received CRT [15].
Sustained improvements in NYHA classiﬁcation and 6-min walk
distance were documented 855 days after implantation. The
cumulative proportion of deaths and heart transplantations at 18
months was 18%. Echocardiographic data at 12 months post-
implantation documented a signiﬁcant reduction in LVESV (248
vs. 269 mL, p¼0.03). Herweg et al. studied 10 patients with
inotrope-dependent NAHF and reported improved outcomes
[10]. These patients underwent CRT-D implantation with inotropic
Fig. 2. The Kaplan–Meier curve showed better outcomes in responders than in
non-responders.
Table 3
Baseline parameters of responders and non-responders.
Responder (n¼6) Non-responder
(n¼23)
p-Value
Age, y 6977 66712 0.85
Male, n 4(67%) 13(56%) 0.55
Ischemic cardiomyopathy, n 3(50%) 5(22%) 0.14
LBBB, n 4(67%) 9(39%) 0.39
QRS width, ms 181722 160741 0.21
Paroxysmal AF, n 1(2%) 8(35%) 0.24
Persistent AF, n 0 5(22%) –
Inotropes, n 3(50%) 14(61%) 0.79
Creatinine 41.5 mg/dL, n 3(50%) 7(30%) 0.41
Systolic BP, mmHg 96714 97716 0.97
LVEF, % 2275 2376 0.44
LVEDV, mL 219766 189778 0.38
LVESV, mL 184756 142763 0.21
MR, degree 1.570.6 1.670.5 0.51
LV dyssynchrony, ms 341748 206780 0.02
BNP, pg/mL 7147358 13527823 0.06
Sodium, mmol/L 13573 13575 0.98
Hemoglobin, g/dL 12.671.3 10.271.8 0.07
LBBB, left bundle branch block; AF, atrial ﬁbrillation; BP, blood pressure; LVEF, left
ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV,
left ventricular end-systolic volume; MR, mitral regurgiation; BNP, brain natriuretic
peptide.
Fig. 3. A plot of left ventricular (LV) dyssynchrony in patients with and without
cardiovascular events. All patients with LV dyssynchrony below 130 ms reached the
primary endpoint. Patients without cardiovascular events presented with signiﬁ-
cantly greater LV dyssynchrony than that in patients with events (p¼0.02).
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support, and all were alive 10887284 days post-implantation
including three patients who underwent cardiac transplantation.
Our study results are essentially consistent with those of prior
reports with regard to safety and long-term outcomes.
To the best of our knowledge, this is the ﬁrst study to analyze
factors predicting response in this severely afﬂicted population of
patients with heart failure undergoing CRT. Our study shows that
similar to other reports on conventional CRT indications, LV
dyssynchrony is signiﬁcantly related to response [8,9]. The STAR
study was the ﬁrst to associate radial strain LV dyssynchrony
(4130 ms) with long-term survival after CRT. Although the STAR
study included NYHA IV patients, it did not describe whether they
were ambulatory. No trials have reported on the usefulness of LV
dyssynchrony prior to CRT implantation in patients with NAHF.
One case report described a 73-year-old man with a pacemaker
who was admitted for refractory heart failure [16]. A speckle
tracking strain identiﬁed severe LV dysfunction and LV dyssyn-
chrony following RV pacing. As the patient's clinical condition
worsened despite optimal medical treatment, a CRT device was
implanted as rescue therapy. After implantation, the patient's
symptoms rapidly improved and an echocardiographic assessment
showed dramatic improvement in his LV systolic function. This
case report suggested that an echocardiographic assessment of
dyssynchrony is useful for deciding on a CRT indication in patients
with refractory heart failure due to RV pacing. Established pre-
dictors of CRT response such as the presence of LBBB and QRS
width are not associated with reverse remodeling. These outcomes
may be the result of a selection bias, because the indication for CRT
implantation was at the discretion of each physician and involved
consideration of various factors including both the electrographic
and echocardiographic status.
In 2004, Auricchio et al. stated, “CRT may be contraindicated in
patients in whom weaning from parenteral inotropic therapy has
not been possible” [17]. Our study showed the reverse in a broader
population of severely ill patients, if they had signiﬁcant LV
dyssynchrony.
The present study had some limitations. First, it was not a
randomized study and the sample size was small. Thus, additional
studies are required to validate our ﬁndings in a large number of
patients. Second, due to the retrospective nature of the study,
many different echocardiographic recording systems were used to
assess cardiac function. Although the same software was used to
analyze speckle-tracking LV dyssynchrony, it may differ from
previously reported data.
5. Conclusion
CRT can be safely used in patients with NAHF and can improve
long-term patient outcomes, especially in treatment responders.
LV dyssynchrony has the potential to predict better outcomes in
this severely afﬂicted population.
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